Neuronetics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- -
- Introduction
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Accelerated TMS for MDD
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Neuronetics
- Target Recruit Count
- 50
- Registration Number
- NCT07147218
- Locations
- 🇺🇸
Brighter Neurotherapeutics, New York, New York, United States
🇺🇸New chapter TMS, Spokane, Washington, United States
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
- Conditions
- DepressionOCDAnxiety Depression
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Neuronetics
- Target Recruit Count
- 12000
- Registration Number
- NCT06997549
- Locations
- 🇺🇸
Neuronetics, Malvern, Pennsylvania, United States
Retrospective Analyses of TrakStar Database
- Conditions
- DepressionAnxiety DepressionObsessive-Compulsive Disorder
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Neuronetics
- Target Recruit Count
- 156000
- Registration Number
- NCT06917339
- Locations
- 🇺🇸
Neuronetics, Malvern, Pennsylvania, United States
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents
- Conditions
- MDD
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Neuronetics
- Target Recruit Count
- 7690
- Registration Number
- NCT06699940
- Locations
- 🇺🇸
Neuronetics, Malvern, Pennsylvania, United States
Symptom Evaluation Following Repetitive Transcranial Magnetic Stimulation
- Conditions
- Neurologic Symptoms
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Neuronetics
- Target Recruit Count
- 20
- Registration Number
- NCT06429748
- Locations
- 🇺🇸
Charlotte Skin and Laser, Charlotte, North Carolina, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Approves TMS for Adolescent Depression: Study Shows Significant Symptom Improvement
A recent study analyzed data from over 1,200 adolescents and young adults treated with Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder (MDD).